{
  "docId": "019dd923-5e88-73ef-bd5c-f812573a947a",
  "docSlug": "eea7524c557036f4",
  "documentTitle": "2020 Air Street Capital The State of AI Report 2020",
  "authorId": "AirStreetCapital",
  "authorName": "Air Street Capital",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 83,
  "pageCount": 177,
  "prevPage": 82,
  "nextPage": 84,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide highlights the efficiency gains of AI in drug discovery, noting a 20% reduction in candidate testing compared to traditional methods.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "logo_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5c-f812573a947a/83",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a#slide-83",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Only 350 candidates were tested in real-world experiments to find DSP-1181. This is around 20% of the normal number of compound candidates that are tested in a typical campaign.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-47c5-73ac-aa67-b3b9e5d4f2ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.02,
        "y": 0.092
      },
      "kind": "image",
      "text": "Exscientia and Sumitomo Dainippon Pharma logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f84031d9-91a1-437d-803a-f2252ae33a73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.29
      },
      "kind": "list",
      "text": "The drug, DSP-1181, acts as an agonist to the receptor for serotonin, a signaling molecule in the brain that mediates mood.\nWhile the mechanism of obsessive-compulsive disorder has not been definitively established, it is believed that increasing serotonin signaling using receptor agonists could improve OCD symptoms.\nThis study used AI techniques to generate tens of millions of potential molecules against the serotonin receptor and sift through the candidates to decide which ones to prioritise for synthesis and testing.\nOnly 350 candidates were tested in real-world experiments to find DSP-1181. This is around 20% of the normal number of compound candidates that are tested in a typical campaign.\nSeparately, Exscientia expanded its commercial partnerships by adding a €240M deal with Bayer on cardiovascular disease and oncology,",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72514683-c619-471f-9f49-4f53876ee868",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.02,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "The result of a 12 month collaboration between British Exscientia and Japanese Sumitomo Dainippon Pharma.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb9e449e-f037-44f3-85fc-3d6acb23f0b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.14
      },
      "kind": "title",
      "text": "The first phase 1 clinical trial of an AI-designed drug begins in Japan to treat OCD patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48159a3d-d37e-40bf-bc78-f2aaeb24dcce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019dd95a-0fd5-7148-8ecf-6334a7dee2c0",
      "evidence": "Title states first phase 1 trial milestone.",
      "confidence": 85
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-ed2a8f38a754",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Research, Talent, Industry sections inventory what happened in AI in 2020.",
      "position": 1,
      "confidence": 60,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-fc384f439bba",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": "mountain-rising-action",
      "evidence": "Research, Talent and Industry sections build momentum of AI progress.",
      "position": 2,
      "confidence": 40,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 89,
      "from": 83,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3d-0f7fddb1083f",
      "evidence": "Phase 1 trial, EUR250M Exscientia deal, mega rounds, MELLODDY, LabGenius.",
      "position": 10,
      "objective": "Show pharma validating AI-first drug discovery",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 75,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}